Tikcro Technologies (TIKRF) 0.4440 $TIKRF Tikcro

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Tikcro Technologies (TIKRF) 0.4440 $TIKRF

Tikcro Technologies Reports First Quarter 2016 Results
PR Newswire - Wed Jun 01, 12:43PM CDT
Tikcro Technologies Ltd. (OTCQX: TIKRF) today reported financial results for the first quarter ended March 31, 2016.

Tikcro Technologies Reports Fourth Quarter and Year End 2015 Results
PR Newswire - Thu Mar 31, 9:01AM CDT
Tikcro Technologies Ltd. (OTCQX: TIKRF) today reported financial results for the fourth quarter and the year ended December 31, 2015.

OTC Markets Group Welcomes Tikcro Technologies to OTCQX
PR Newswire - Tue Dec 29, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial markets, today announced Tikcro Technologies Ltd. (OTCQX: TIKRF), an Israel-based developer of second generation antibodies binding to cancer-immune modulators, currently in pre-clinical stage, has qualified to trade on the OTCQX® Best Market.

Tikcro Adds New Cancer Immune Modulators Targets
PR Newswire - Tue Dec 15, 3:05PM CST
Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that it has extended an ongoing research and license agreement with Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science in Israel, for additional targets for cancer immune modulators generated from a certain lab at the Weizmann Institute of Science.

Tikcro Technologies Announces 2015 Annual General Meeting
PR Newswire - Tue Nov 24, 7:30AM CST
Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting of Shareholders will be held on December 29, 2015 at 11:00 a.m. Israel time, at the law offices of Goldfarb Seligman & Co., Electra Tower, 98 Yigal Allon Street, 36th Floor, Tel Aviv, Israel.

Tikcro Technologies Launches New Website
PR Newswire - Mon Oct 26, 10:37AM CDT
Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced the launch of a new corporate website. The website features information on the Company's approach of using a novel 3D antigen design methodology to generate antibodies for the treatment of certain cancer indications by addressing immune modulators. Specifically, it describes the Company's product pipeline of antibodies for the blocking of CTLA4 and PD1 interactions with its respective ligands. The website also has a comprehensive investor section with up to date financial information and a corporate presentation. The new website is located at www.tikcro.com.

Tikcro Technologies Reports Second Quarter 2015 Results
PR Newswire - Tue Jul 14, 10:31AM CDT
Tikcro Technologies Ltd. (OTCQB: TIKRF) today reported results for the second quarter ended June 30, 2015.

Tikcro to Proceed with CTLA4 and PD1 Antibody Generation Plan
PR Newswire - Mon Jun 15, 7:30AM CDT
Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that it will proceed with a pre-clinical plan for the generation and verification of new antibodies targeting the modulation of CTLA4 and PD1 cancer checkpoints.

Tikcro Technologies Announces Approval to Continue Trading on OTCQB
PR Newswire - Tue May 05, 8:42AM CDT
Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that the Company was approved to continue trading on OTCQB Marketplace, the market for developmental stage companies.

Tikcro Technologies Announces Shareholders' Meeting
PR Newswire - Wed Feb 18, 8:00AM CST
Tikcro Technologies Ltd. (OTC PK: TIKRF) today announced that an Extraordinary General Meeting of Shareholders will be held on March 25, 2015 at 12:00 p.m. Israel time, at the law offices of Goldfarb Seligman & Co., Electra Tower, 98 Yigal Allon Street, 36th Floor, Tel Aviv, Israel.

Tikcro Signs Research and License Agreement Regarding Cancer Immune Checkpoint Antibodies
PR Newswire - Tue Dec 30, 8:00AM CST
Tikcro Technologies Ltd. (OTC PK: TIKRF) today announced that it has entered into a research and license agreement with Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science in Israel. This agreement is for the development of new antibodies originating from specified research at the Weizmann Institute of Science addressing identified targets of cancer immune checkpoints.

Tikcro Technologies Reports Third Quarter 2014 Results
PR Newswire - Thu Nov 13, 8:00AM CST
Tikcro Technologies Ltd. (OTC PK: TIKRF) today reported results for the third quarter ended September 30, 2014.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 7

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 6

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 8

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 8

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 11

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 12

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 5

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 12

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 11

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading

Top 5 Most Recently Viewed Articles

A Closer Look at Marvell Tech's Upcoming Earnings Release

Updated Category News Views 184

Marvell Tech's Expected Earnings Release Marvell Tech (NASDAQ: MRVL) is set to announce its latest quarterly earnings in December. As investors await this critical financial moment, a brief review of what to expect can shed light on potential impacts and opportunities. Analysts' Earnings Projections Analysts forecast that Marvell Tech will achieve an earnings per share...

Continue Reading
Banijay Group's Recent Share Transactions Update and Insights

Updated Category News Views 222

Recent Share Transactions Overview Banijay Group N.V. (ISIN: NL0015000X07, Bloomberg: BNJ NA, Reuters: BNJ.AS) has reported on its recent share transactions, showcasing the buying and selling activities from the period of September 22 to September 26. Understanding Share Transactions During this timeframe, a mix of buying and selling occurred within the company’s...

Continue Reading
Strategic Growth for Voyageur Mineral Explorers via New Offering

Updated Category News Views 143

Voyageur Mineral Explorers Corp. Secures Massive Funding Voyageur Mineral Explorers Corp. (CSE: VOY) has recently made headlines by completing a significant brokered offering, raising $37.5 million. This financial boost comes at a crucial time for the Company as it seeks to expand its operations and investments in the mineral exploration sector. The offering was executed...

Continue Reading
Applied Materials Faces Challenges Amid Weak Outlook and Stocks

Updated Category News Views 114

Applied Materials Inc. Stock Performance Applied Materials Inc. (NASDAQ: AMAT) recently experienced a noticeable decline in its stock value as the company shared its financial results. After the market closure, the organization revealed its third-quarter earnings, leading to significant concern among investors. The stock's value tumbled, reflecting the market's reaction...

Continue Reading
VFC Class Action Demands Attention: Key Details for Investors

Updated Category News Views 192

Understanding the VFC Class Action Lawsuit Investors in V.F. Corporation, commonly known as VFC, should pay close attention to a pending class action lawsuit that could have significant implications. The law firm Faruqi & Faruqi, a reputable name in securities litigation, has stepped forward to represent affected investors. They are drawing attention to a critical...

Continue Reading